AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02633813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftifine hydrochloride 2%
Description: Topical application for two weeks
Study NCT03635567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to pembrolizumab
Description: IV infusion
Study NCT02612584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinhole Soft Contact Lens apply for presbyopia
Study NCT02906306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Occupational Therapy
Description: 45 minutes 3 times per week 6 months in nursing homes (A and B)
Study NCT03167060 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Rhinochill
Description: Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device.
Study NCT01844596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral communication strategy
Description: Community Health Workers with an additional tailored behavioral communication strategy.
Study NCT01844596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral communication strategy, plus smartphone-based tool
Description: Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
Study NCT02906306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Occupational Therapy
Description: 45 minutes 3 times per week 6 months in nursing homes (A and B)
Study NCT04144517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemvaleukin Alfa
Description: Nemvaleukin alfa IV infusion.
Study NCT04144517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.
Study NCT03899428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV (intravenous infusion)
Study NCT02162667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
Study NCT03899428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Prescribed by physician.
Study NCT03899428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Prescribed by physician.
Study NCT03899428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Prescribed by physician.
Study NCT03899428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Prescribed by physician.
Study NCT03664544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg MCI-186 will be administered intravenously over 60 minutes.
Study NCT03632044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia
Study NCT03632044 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
Study NCT04933305 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Description: Laparoscopic surgical procedure
Study NCT03003143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin 500 MG
Study NCT03568149 — intervention group
Intervention type: PROCEDURE
Intervention: assessment of pain symptoms at first medical examination
Description: First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
Study NCT02976805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4L PegLyte + 15 mg bisacodyl
Description: Randomized
Study NCT02976805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6L PegLyte + 15 mg bisacodyl
Description: Randomized
Study NCT00933478 — intervention group
Intervention type: DEVICE
Intervention: Clay
Description: Small dime sized piece of clay.
Study NCT04093453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sodium Chloride)
Description: Participant receive Placebo (Sodium Chloride)
Study NCT04093453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 1 hour exercise
Study NCT04093453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour exercise
Study NCT04093453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Propionate
Description: Participant receive Sodium Propionate
Study NCT02162667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
Study NCT04649099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaflex™ Performer
Description: A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
Study NCT02633813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application for two weeks
Study NCT02633813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftin® 2% (Naftifine hydrochloride 2%)
Description: Topical application for two weeks
Study NCT01085474 — intervention group
Intervention type: OTHER
Intervention: 1
Description: In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
Study NCT04175015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartie© sweet/candy
Description: one chocolate sweet/ chocolate candy
Study NCT04175015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartie© sweet/candy
Description: one chocolate sweet/ chocolate candy
Study NCT04339777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan test dose
Description: 0.8 mg/kg IV infusion over 2 hours
Study NCT04339777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 40 mg/m2 IV infusion over 30 min once daily for 4 days
Study NCT04339777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 10/10 Matched Related and Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 4 days (-6, -5, -4, and -3).~For Intermediate Intensity Arm, the busulfan dose will be given for 3 days (-6,-5, and -4).~For Low Intensity Arm, the busulfan dose will be given for 2 days on days (-6 and -5). 9/10 HLA Matched Related or Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 3 days (-6,~-5, and -4). For the the Intermediate Intensity Arm, the busulfan dose will be given for 2 days (-6 and -5).~For the Low Intensity Arm, the busulfan dose will be given for 1 day on day (-6).
Study NCT04339777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Alemtuzumab will be given if there is evidence of immune dysregulation 10 mg/m2 SC divided over three days (-14, -13, and -12)
Study NCT01085474 — intervention group
Intervention type: OTHER
Intervention: 2
Description: The best intervention used in the pilot study will be chosen and included in the main study.
Study NCT03141593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D: liquid form, start weekly
Description: Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
Study NCT03141593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D: liquid form, start monthly
Description: Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
Study NCT03141593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D: solid form, start weekly
Description: Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
Study NCT03141593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D: solid form, start monthly
Description: Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
Study NCT00611208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-dmDT390-bisFv(UCHT1)
Description: A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
Study NCT05283278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine
Description: Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A
Study NCT05283278 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine and probiotics
Description: Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day in combination with the probiotic Lactobacillus Delbrueckii and Lactobacillus Fermentum (Lacteol fort®) given in a dose of 5 billions starting from birth to the 30th day of life for neonates in group B
Study NCT05283278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given starting from birth to the 30th day of life for neonates in group C.
Study NCT01942967 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Measurement of:~* Left ventricular output (LVO).~* Right ventricular output (RVO).~* Assessment of the Mesenteric Artery Flow.
Study NCT01942967 — intervention group
Intervention type: OTHER
Intervention: Near Infrared Spectroscopy Monitoring
Description: Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
Study NCT03189134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescite
Description: Dilute fluorescite will be applied to cardiac tissue prior to imaging
Study NCT03189134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio 100 Series System with Confocal Miniprobes
Description: Microscopy system will image cardiac tissue.
Study NCT02799095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 4230
Description: Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
Study NCT02799095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 4230 + pembrolizumab
Description: IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
Study NCT01916889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RACY test
Study NCT01520350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Adjunctive Aripiprazole
Description: low-dose 2-5mg/d for 8 weeks
Study NCT01520350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT03241654 — intervention group
Intervention type: PROCEDURE
Intervention: flow trigger
Description: The flow trigger will be adjust during the pressure assist ventilation.
Study NCT03568149 — intervention group
Intervention type: PROCEDURE
Intervention: assessment of pelvic vascular insufficiency signs
Description: Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~* Ovarian vein diameter \<4mm~* Slow ovarian blood flow (\<3cm/sec)~* Retrograde blood flow~* Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~* Standard 2D study, to measure vessels diameter~* Vascular doppler study, to evaluate flow direction and blood speed~* 3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree.
Study NCT03232424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A
Description: * Begins the day prior to radiotherapy start and continues until the end of temozolomide maintenance cycle #2 or until evidence of disease progression or unacceptable toxicity.~* Arrays are removed immediately prior to radiotherapy and replaced immediately thereafter.
Study NCT03232424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concomitant phase:~* 75 mg/m2 per day for 42 days concomitant with radiotherapy.~* Begins 1 day prior to XRT start.~Maintenance phase:~* Begins 4 weeks after concomitant phase completion (+/- 1 week).~* Each cycle is 28 days (5 days of drug treatment followed by 23 days without).~* Cycle 1: 150 mg/m2 once daily for the first 5 days of each treatment cycle.~* Subsequent cycles: daily dose increased to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.
Study NCT03232424 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal or intensity modulated radiation therapy (IMRT)
Description: Radiotherapy will commence 4 weeks after the definitive surgical procedure (+/- 1 week), to a total dose of 54.0 - 60.0 Gy, delivered in 1.8 - 2.0 Gy fractions over 6 - 7 weeks. XRT target volumes will be determined utilizing all available imaging studies that best delineate extent of disease. Fusion image registration for treatment planning will be utilized as possible. Either 3D conformal or intensity modulated radiation therapy (IMRT) will be utilized.
Study NCT02432560 — intervention group
Intervention type: DRUG
Intervention: Sirolimus
Description: Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
Study NCT02432560 — intervention group
Intervention type: DRUG
Intervention: Everolimus
Description: Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
Study NCT02969343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Safety health information technology
Description: Patient safety technology toolkits on hospital care units
Study NCT04339777 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total body Irradiation
Description: 200 cGy Transplant Day -1 (Only for 9/10 HLA Matched Related or Unrelated Donor Recipients )
Study NCT01519245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
Study NCT01519245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
Study NCT04339777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic HSCT
Description: Stem cell transplant
Study NCT03041987 — intervention group
Intervention type: OTHER
Intervention: Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc
Study NCT01474083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK1-399 (formerly TTP399)
Description: Treatment A: GK1-399 200 mg. Oral administration, twice per day.
Study NCT04339777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Tacro)
Description: Tacrolimus 0.02 mg/kg IV continuous infusion over 24 hours starting on day +5
Study NCT04339777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Mycophenolate mofetil 15 mg/kg IV over 2 hours three times a day starting on day +5 will continue until Approximately+35 (+/- two days)
Study NCT04339777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (Cytoxan)
Description: Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight
Study NCT03424733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plegridy
Description: Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
Study NCT03424733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plegridy
Description: Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
Study NCT03424733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
Study NCT03424733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
Study NCT03424733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol Pill
Description: Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
Study NCT03424733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol Pill
Description: Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
Study NCT05770973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany
Description: Compression dressing after ptosis surgery
Study NCT02719509 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Ultrasound
Study NCT01474083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK1-399 (formerly TTP399)
Description: Treatment B: GK1-399 800 mg. Oral administration, once per day.
Study NCT01474083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK1-399 (formerly TTP399)
Description: Treatment C: GK1-399 800 mg. Oral administration, twice per day.
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Carboplatin
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Carboplatin
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU) plus carboplatin or cisplatin
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobolimab
Study NCT02723955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Study NCT01987986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: injectible intervention
Study NCT01987986 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03901612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Description: Continuous post operative regional analgesia
Study NCT03901612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 09%
Description: Continuous post operative regional analgesia
Study NCT04680286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Hydrochloride
Description: Single dose, intravenous bolus, 0,1 mg/kg administered at induction of anesthesia.